Trade Puma Biotechnology, Inc. - PBYI CFD

Trading Conditions
Spread0.0400
Long position overnight fee
Long position overnight fee

Margin. Your investment
US$1,000.00
Overnight fee
Charges from full value of position
-0.026179 %
(-US$1.05)

Trade size with leverage ~ US$5,000.00

Short position overnight fee ~ US$4,000.00


-0.026179%
Short position overnight fee
Short position overnight fee

Margin. Your investment
US$1,000.00
Overnight fee
Charges from full value of position
0.003957 %
(US$0.16)

Trade size with leverage ~ US$5,000.00

Short position overnight fee ~ US$4,000.00


0.003957%
Overnight fee time21:00 (UTC)
CurrencyUSD
Min traded quantity1
Margin20
Stock exchangeUnited States of America
Commission on trade10%

Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close4.8
Open4.75
1-Year Change74.84%
Day's Range4.7 - 4.92

Puma Biotechnology Company profile

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.